Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer
Status:
Unknown status
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and safety the combination of
TRANSKRIP ® vs placebo plus Carboplatin/Paclitaxel as first line treatment in patients with
recurrent-persistent cervical cancer.